Literature DB >> 33330827

Early hemodynamics of hepatocellular carcinoma using contrast-enhanced ultrasound with Sonazoid: focus on the pure arterial and early portal phases.

Akiko Saito1, Masakazu Yamamoto2, Satoshi Katagiri2, Shingo Yamashita2, Masayuki Nakano3, Toshio Morizane4.   

Abstract

To clarify the early hemodynamics of hepatocellular carcinoma (HCC), we defined the early portal phase of contrast-enhanced ultrasound (CEUS) and examined the reliability of this modality for determining HCC differentiation. Starting in 2007, we performed Sonazoid CEUS in 146 pathologically confirmed hepatic nodules; 118 HCC (8 poorly [Pd], 73 moderately [Md] and 37 well-differentiated [Wd]) and 28 benign nodules. We focused on the pure arterial and early portal phases up to 45 seconds after Sonazoid injection, and then the subsequent phase up to 30 minutes. We calculated covariance-adjusted sensitivities for nodule enhancement combinations of these three phases. Nodule enhancements were divided into hypo, iso and hyper. A positive predictive value of 100% was obtained for the following patterns: iso-iso-hypo, hypo-iso-iso, and hypo-hypo-hypo for Wd, hyper-iso-hypo and hyper-hypo-hypo for Md, hypo-hyper-hypo for Pd, and hyper-hyper-hyper for benign nodules. In Wd HCC (early HCC), there were seven enhancement patterns, thought to be characterized by various hemodynamic changes from early to advanced HCC. Two patterns allowing a diagnosis of Wd HCC were hypo in the pure arterial phase. Subsequent iso-enhancement in the early portal phase indicated a portal blood supply. Decreased enhancement in the early portal phase allows a diagnosis of Md HCC. However, gradual enhancement observed from the pure arterial to the early portal phase allows a diagnosis of Pd HCC. Therefore, even in the early portal phase, hemodynamic changes were visible not only in Wd but also in Md and Pd HCC. In conclusion, with division of the early phase hemodynamics into pure arterial and early portal phases, CEUS can provide information useful for determining the likely degree of HCC differentiation and for distinguishing early stage HCC from benign nodules. 2020, National Center for Global Health and Medicine.

Entities:  

Keywords:  contrast-enhanced ultrasonography; early HCC; histological differentiation; well-differentiated HCC

Year:  2020        PMID: 33330827      PMCID: PMC7731175          DOI: 10.35772/ghm.2020.01092

Source DB:  PubMed          Journal:  Glob Health Med        ISSN: 2434-9186


  23 in total

1.  Computer-aided diagnosis for contrast-enhanced ultrasound in the liver.

Authors:  Katsutoshi Sugimoto; Junji Shiraishi; Fuminori Moriyasu; Kunio Doi
Journal:  World J Radiol       Date:  2010-06-28

2.  Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells.

Authors:  Kyosuke Yanagisawa; Fuminori Moriyasu; Takeo Miyahara; Miyata Yuki; Hiroko Iijima
Journal:  Ultrasound Med Biol       Date:  2007-02       Impact factor: 2.998

3.  Identifiability of models for multiple diagnostic testing in the absence of a gold standard.

Authors:  Geoffrey Jones; Wesley O Johnson; Timothy E Hanson; Ronald Christensen
Journal:  Biometrics       Date:  2010-09       Impact factor: 2.571

4.  Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.

Authors:  Eleonora Terzi; Massimo Iavarone; Maurizio Pompili; Letizia Veronese; Giuseppe Cabibbo; Mirella Fraquelli; Laura Riccardi; Ludovico De Bonis; Angelo Sangiovanni; Simona Leoni; Maria Assunta Zocco; Sandro Rossi; Nicola Alessi; Stephanie R Wilson; Fabio Piscaglia
Journal:  J Hepatol       Date:  2017-11-11       Impact factor: 25.083

5.  Depiction of portal supply in early hepatocellular carcinoma and dysplastic nodule: value of pure arterial ultrasound imaging in hepatocellular carcinoma.

Authors:  Masatoshi Kudo; Kinuyo Hatanaka; Tatsuo Inoue; Kiyoshi Maekawa
Journal:  Oncology       Date:  2010-07-08       Impact factor: 2.935

6.  Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update.

Authors:  Norihiro Kokudo; Nobuyuki Takemura; Kiyoshi Hasegawa; Tadatoshi Takayama; Shoji Kubo; Mitsuo Shimada; Hiroaki Nagano; Etsuro Hatano; Namiki Izumi; Shuichi Kaneko; Masatoshi Kudo; Hiroko Iijima; Takuya Genda; Ryosuke Tateishi; Takuji Torimura; Hiroshi Igaki; Satoshi Kobayashi; Hideyuki Sakurai; Takamichi Murakami; Takeyuki Watadani; Yutaka Matsuyama
Journal:  Hepatol Res       Date:  2019-09-06       Impact factor: 4.288

7.  Utility of Contrast-enhanced Ultrasonography with Perflubutane for Determining Histologic Grade in Hepatocellular Carcinoma.

Authors:  Toshifumi Tada; Takashi Kumada; Hidenori Toyoda; Takanori Ito; Yasuhiro Sone; Yuji Kaneoka; Atsuyuki Maeda; Seiji Okuda; Katsuhiko Otobe; Kenichi Takahashi
Journal:  Ultrasound Med Biol       Date:  2015-09-07       Impact factor: 2.998

8.  Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation.

Authors:  Hyun-Jung Jang; Tae Kyoung Kim; Peter N Burns; Stephanie R Wilson
Journal:  Radiology       Date:  2007-09       Impact factor: 11.105

9.  New malignant grading system for hepatocellular carcinoma using the Sonazoid contrast agent for ultrasonography.

Authors:  Hironori Tanaka; Hiroko Iijima; Akiko Higashiura; Kazunori Yoh; Akio Ishii; Tomoyuki Takashima; Yoshiyuki Sakai; Nobuhiro Aizawa; Kazunari Iwata; Naoto Ikeda; Yoshinori Iwata; Hirayuki Enomoto; Masaki Saito; Hiroyasu Imanishi; Seiichi Hirota; Jiro Fujimoto; Shuhei Nishiguchi
Journal:  J Gastroenterol       Date:  2013-05-30       Impact factor: 7.527

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  1 in total

1.  Prediction of early recurrence of HCC after hepatectomy by contrast-enhanced ultrasound-based deep learning radiomics.

Authors:  Hui Zhang; Fanding Huo
Journal:  Front Oncol       Date:  2022-09-28       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.